JC Biotech
JC Biotech Private Limited is an Indian specialty fermentation manufacturer founded in 2004 that produces the bio-pharmaceutical API Serratiopeptidase and DHA omega-3 oil from a GMP-compliant plant in Andhra Pradesh, selling B2B to pharmaceutical and nutraceutical manufacturers in India.
- Company typePrivate
- Founded2004
- HeadquartersHyderabad, India
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What JC Biotech does
JC Biotech Private Limited is an Indian specialty fermentation manufacturer founded in 2004 that produces nutraceuticals, bio-pharmaceuticals, and biochemicals used in the synthesis of active pharmaceutical ingredients (APIs). The company operates a 30-acre GMP-compliant manufacturing site at the APIIC Growth Centre in Prakasam District, Andhra Pradesh, supported by a corporate office in Hyderabad, Telangana. It was established under the guidance of Late Sri. S. Koteswara Rao, founder of Bhagiradha Chemicals & Industries, with S. Chandra Sekhar serving as Promoter and Managing Director.
The company's core technology is a semi-automated aerobic fermentation platform with fermenter capacities ranging from 50 L to 33,000 L, monitored via a Distributed Control System (DCS) for temperature, pH, and dissolved oxygen, and complemented by a versatile downstream processing train (membrane filtration, extraction, centrifugation, Nutsche/Sparkler filtration, tray drying and lyophilization) that can simultaneously process two products. In-house synthetic chemistry capability covers esterification, trans-esterification, hydrogenation, chlorination, and halex reactions, with fermenters and vessels fabricated to ASME Sec VIII Div 1 2001 and ASME BPE 2005 codes. Marketed products are Serratiopeptidase (a Serratia marcescens-derived protease API compliant with Indian Pharmacopoeia 2010, with activity up to 2600 u/mg) and DHA 35% oil (an omega-3 ingredient from Schizochytrium microalgae fermentation); a four-product pipeline (Sirolimus, Pneumocandin B0, Thymine, Beta-Thymidine) was disclosed for March 2012 commercialization. JC Biotech became the first company to obtain Indian Pharmacopoeia drug licences for Serratiopeptidase in June 2011, providing an early regulatory foothold.
Revenue is generated through a quote-based B2B ingredient sales model, with Serratiopeptidase priced per u/mg activity and DHA oil priced per kg, sold directly to pharmaceutical and nutraceutical manufacturers primarily in India. The go-to-market motion is relationship-driven enterprise field sales (phone, fax, email, contact form) with no self-serve, marketplace, or digital channels. The company employs 11-50 people, has not disclosed external investors, and has not reported revenue; cumulative disclosed plant investment stands at Rs. 42.0 crores, with operations confirmed through the FY 2021-2022 CSR Annexure.
JC Biotech firmographics
Firmographics- Name
- JC Biotech
- Legal name
- JC Biotech Private Limited
- Website
- https://jcbiotech.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- JC Biotech Private Limited is an Indian specialty fermentation manufacturer founded in 2004 that produces the bio-pharmaceutical API Serratiopeptidase and DHA omega-3 oil from a GMP-compliant plant in Andhra Pradesh, selling B2B to pharmaceutical and nutraceutical manufacturers in India.
- Ownership category
- akta.pro rank
JC Biotech industry classification
Industry- Product category
- Bio-pharmaceutical API Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Dairy Product Manufacturing (3115), Food Manufacturing (311)
- SIC
- Dairy Products (2020), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836), Food And Kindred Products (2000), Industrial Organic Chemicals (2860)
- akta.pro industry
- Compounding Ingredient & API Distributors (Pharma Supply)Small-Molecule API Commercial ManufacturingHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing ServicesBiologic API/Drug Substance Manufacturing Services
Keywords
Where JC Biotech is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Markets served
JC Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Serratiopeptidase API sales: B2B sale of Serratiopeptidase as an active pharmaceutical ingredient (API) manufactured through aerobic fermentation of Serratia marcescens, supplied as off-white to cream-coloured powder with activity up to 2600 u/mg, compliant with Indian Pharmacopeia 2010 specifications.
- DHA (Docosahexaenoic Acid) oil sales: B2B sale of DHA 35% oil produced by fermentation from marine microalgae Schizochytrium sp., supplied as fluid to waxy pale yellow to orange oil, marketed to nutraceutical manufacturers (min. 32% DHA content).
- Pipeline / R&D product commercialization: Future revenue from commercialization of R&D pipeline products (Sirolimus CAS 53123-88-9; Pneumocandin B0 CAS 135575-42-7; Thymine CAS 65-71-4; Beta-Thymidine CAS 50-89-5) targeted for launch by March 2012.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | Quote-based B2B ingredient pricing |
Go-to-market motion1 record
JC Biotech product offering
Product offeringCore offering
JC Biotech manufactures nutraceutical, bio-pharmaceutical, and biochemical active pharmaceutical ingredients (APIs) using aerobic fermentation. Its commercial products include Serratiopeptidase (a proteolytic enzyme API) and DHA 35% oil (an omega-3 fatty acid), sold B2B to pharmaceutical and nutraceutical manufacturers. The company also has an R&D pipeline of fermentation/synthetic products targeted for future commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- Serratiopeptidase Serratiopeptidase is a proteolytic enzyme (protease, 52 KD molecular weight) produced by Serratia marcescens through aerobic fermentation. It is identified and analyzed per Indian Pharmacopeia 2010, supplied as an off-white to cream coloured powder with typical activity of 2120 u/mg, customizable up to 2600 u/mg. Sold as an API to pharmaceutical manufacturers.
- DHA (Docosahexaenoic Acid) Oil
Companies that use JC Biotech
Customer profileIdeal customer profiles1 record
JC Biotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
JC Biotech partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
JC Biotech competitors and assessment
Company assessmentBroad incumbents
- Biocon Limited: Indian biopharmaceutical company with substantial fermentation-based biologics and API manufacturing; while much larger and biologics-focused, it is a relevant comparable for Indian fermentation API infrastructure and a potential strategic acquirer.
- Laurus Labs: Larger Indian API and CDMO platform with fermentation, synthetic chemistry and finished dosage capabilities; competes with JC Biotech in the broader Indian API market and could be a strategic acquirer of a niche fermentation asset like JC Biotech.
- Divis Laboratories: One of India's largest API manufacturers with strong fermentation and synthetic-chemistry capabilities supplying global generics; relevant comparable for JC Biotech's scale-up trajectory and as a potential strategic partner for international expansion.
- Piramal Pharma Solutions: Global CDMO/API services platform with significant fermentation capacity; comparable technology base and could be a strategic partner or acquirer interested in JC Biotech's fermentation platform and Indian manufacturing footprint.
- Aurobindo Pharma: Large Indian vertically-integrated pharma with significant fermentation-based API manufacturing; while much bigger, it operates in the same Indian API supply ecosystem and is a potential bulk buyer or competitor for JC Biotech's Serratiopeptidase output.
Direct peers
- Fermenta Biotech Limited: Indian fermentation company producing vitamin D3, penicillin derivatives and other fermentation APIs/enzymes; comparable fermentation-driven API business model and Indian mid-cap scale relevant to JC Biotech's Serratiopeptidase and DHA franchise.
- Concord Biotech: Indian fermentation-based API manufacturer specializing in immunosuppressants and other high-value fermentation APIs; directly comparable technology stack (microbial fermentation, downstream purification) and product overlap with JC Biotech's Sirolimus pipeline ambitions.
- Anthem Biosciences: Bengaluru-based fermentation-driven contract development and manufacturing organization focused on APIs and intermediates; comparable in scale and fermentation platform to JC Biotech and competes for similar Indian and global API customers.
- Bhagiradha Chemicals & Industries Limited: Founded by S. Koteswara Rao (the mentor under whom JC Biotech was incubated), Bhagiradha is an Indian specialty chemicals and crop-science/API manufacturer with overlapping fermentation/synthetic chemistry capability and a similar Hyderabad footprint, making it the closest lineage and capability peer.
Emerging players
- Pharmanza Herbal: Smaller Indian API and nutraceutical ingredient manufacturer; comparable in scale and product mix (APIs plus nutraceutical ingredients) to JC Biotech and a useful peer for small-cap Indian specialty ingredient valuation reference.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
JC Biotech social profiles
Digital presenceJC Biotech compliance and trust
Trust signalCompliance3 records
JC Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
JC Biotech leadership team
Management profileNumber of profiles
Profiles1 record
JC Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
JC Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about JC Biotech
What does JC Biotech do?
JC Biotech manufactures nutraceutical, bio-pharmaceutical, and biochemical active pharmaceutical ingredients (APIs) using aerobic fermentation. Its commercial products include Serratiopeptidase (a proteolytic enzyme API) and DHA 35% oil (an omega-3 fatty acid), sold B2B to pharmaceutical and nutraceutical manufacturers. The company also has an R&D pipeline of fermentation/synthetic products targeted for future commercialization.
Is JC Biotech a public or private company?
JC Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was JC Biotech founded?
JC Biotech was founded in 2004. It employs 51 to 100 people.
Where is JC Biotech based?
JC Biotech is headquartered in Hyderabad, India, in the Asia region.
How does JC Biotech make money?
Three revenue lines are on record. Serratiopeptidase API sales are the primary driver. The others are DHA (Docosahexaenoic Acid) oil sales and pipeline / R&D product commercialization.
Who are JC Biotech's main competitors?
Broad incumbents on record are Biocon Limited, Laurus Labs, Divis Laboratories, Piramal Pharma Solutions and Aurobindo Pharma. Direct peers are Fermenta Biotech Limited, Concord Biotech, Anthem Biosciences and Bhagiradha Chemicals & Industries Limited. Pharmanza Herbal is listed as an emerging player.
Does JC Biotech have an API?
No public API is recorded for JC Biotech.
What industry is JC Biotech in?
JC Biotech's product category is Bio-pharmaceutical API Manufacturing. Its primary akta.pro industry code is HLAIAJAO, Compounding Ingredient & API Distributors (Pharma Supply), with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325414 and its SIC code is 2020.